CCBR-SYNARC has the capability to perform large phase III and phase IV trails including extensions of phase II trials in order to meet what ever regulatory requests from the FDA or EMEA concerning efficacy and safety and in the future which pain mechanisms are involved. From a mechanism based perspective it is an advantage to include bio-markers in clinical studies together with the traditional clinical scores. This provides a valuable additional mechanistic understanding of the drug action.
Working with CCBR speeds up and drives efficiencies in clinical trials by offering greater numbers of patients across fewer sites
A Global Footprint covering more than 20 dedicated Clinical Research Centers in high density population areas
Uniform SOPs enable the tightest possible adherence to study protocols and consistency across all CCBR sites
Real-Time tacking of subject enrolment and trial progress ensures sponsors have the most up to date information, all of the time
Centralised, standardised billing affords better visibility into trial costs for sponsors
